Target intelligence / Profile preview

Alpha/beta hydrolase domain-containing protein 6 (ABHD6)

Target
ABHD6
Molecular classification
Enzyme, Hydrolase, Serine hydrolase, Lipase
01

Overview

Alpha/beta hydrolase domain-containing protein 6 (ABHD6) is a membrane-bound serine hydrolase that serves as a key regulator of the endocannabinoid system by hydrolyzing 2-arachidonoylglycerol (2-AG), the most abundant endogenous ligand for cannabinoid receptors (UniProt, Q9BV71). Although monoacylglycerol lipase (MAGL) accounts for the majority of 2-AG degradation in the brain, ABHD6 provides localized control of 2-AG signaling at the synapse, particularly at the postsynaptic membrane where it acts as a gatekeeper for CB1 receptor activation (PubMed, 22403446). Beyond the central nervous system, ABHD6 is highly expressed in pancreatic beta cells and liver tissue, where it regulates insulin secretion and lipid accumulation by modulating monoacylglycerol levels (PubMed, 24439591).

Pharmacological inhibition of ABHD6 has emerged as a promising strategy for treating a variety of conditions, including neuroinflammatory diseases like multiple sclerosis and metabolic disorders such as type 2 diabetes (PubMed, 26949163). By elevating 2-AG levels, ABHD6 inhibitors like WWL70 and KT182 exert anti-inflammatory and neuroprotective effects in preclinical models (PubChem, CID 25154897). However, the therapeutic application of ABHD6 inhibitors requires careful consideration of selectivity within the serine hydrolase superfamily to avoid unintended metabolic or neurological side effects. Current research continues to explore its potential as a target for modulating both central neurotransmission and peripheral energy homeostasis.

Other names
Monoacylglycerol lipase ABHD6Abhydrolase domain-containing protein 6ABH6
02

Mechanism of action

Inhibition of ABHD6 enzymatic activity to increase levels of 2-arachidonoylglycerol (2-AG), thereby enhancing cannabinoid receptor signaling.

03

Biological functions

Lipid metabolismSignal transductionEndocannabinoid signalingNeurotransmission modulationInsulin secretion regulation
04

Disease associations

InflammationNeurodegenerative diseaseMetabolic diseaseObesityType 2 diabetesEpilepsyMultiple sclerosisTraumatic brain injury
05

Safety considerations

Off-target inhibition of other serine hydrolasesPotential for CB1-mediated psychiatric side effectsAlterations in systemic lipid metabolism
06

Interacting drugs

WWL70

4 more in the full profile.

07

Biomarkers

2-arachidonoylglycerol (2-AG) levels1-monoacylglycerol levelsMonoacylglycerol lipase activity

Beyond the preview

Go deeper on Alpha/beta hydrolase domain-containing protein 6 (ABHD6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha/beta hydrolase domain-containing protein 6 (ABHD6).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call